Paradoxical exacerbation of myoclonic-astatic seizures by levetiracetam in myoclonic astatic epilepsy

BMC Pediatrics

Ahmad Beydoun¹  Ahmad Fawaz¹  Wassim Nasreddine¹  Ghassan Hmaimess²  Yamane Makke¹ 

[1] Department of Neurology, American University of Beirut Medical Center, Beirut, Lebanon;Department of Pediatric, St George Hospital Medical University Center, University of Balamand, Beirut, Lebanon

关键词: Myoclonus;    Levetiracetam;    Antiepileptic;    Doose syndrome;    Electroclinical syndrome;    Epilepsy;   

Others  :  1127163
DOI  :  10.1186/s12887-015-0330-y

 received in 2014-06-05, accepted in 2015-01-07,  发布年份 2015

【 摘 要 】

Background

Levetiracetam is a broad spectrum antiepileptic drug (AED) with proven efficacy when used as adjunctive therapy against myoclonic seizures. We report two patients suffering from epilepsy with myoclonic-astatic epilepsy (MAE) who experienced a paradoxical worsening of seizures after initiation of treatment with LEV, a finding not previously described.

Case presentation

Patients included were enrolled in an ongoing large prospective study evaluating children and adults with new onset epilepsy in Lebanon conducted at the American University of Beirut Medical Center in association with the Lebanese Chapter of the International League against Epilepsy. Based on an extensive evaluation, these patients were stratified into idiopathic partial, idiopathic generalized, symptomatic partial or symptomatic generalized epilepsies. Whenever possible the electroclinical syndrome was identified according to the ILAE classification of epilepsy syndromes. Patients were subsequently followed up on regular intervals and were assessed for adverse events, and seizure recurrence.

MAE was diagnosed in five (1.6%) out of 307 consecutive children enrolled in this study. LEV was used as adjunctive therapy in four of those children with two experiencing a substantial and dose related worsening in the frequency of their myoclonic and atonic seizures.

Conclusion

LEV should be used with caution in children with MAE and an exacerbation of seizure frequency temporally related to the introduction of LEV should alert the clinician to the possibility of a paradoxical seizure exacerbation.

【 授权许可】

   
2015 Makke et al.; licensee BioMed Central.

【 参考文献 】

• [1]Beydoun A, D'Souza J: Treatment of idiopathic generalized epilepsy-a review of the evidence. Expert Opin Pharmacother 2012, 13:1283-98.
• [2]Noachtar S, Andermann E, Meyvisch P, Andermann F, Gough W, Schiemann-Delgado J: Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurology 2008, 70:607-16.
• [3]Berkovic S, Knowlton R, Leroy R, Schiemann J, Falter U: Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy. Neurology 2007, 69:1751-60.
• [4]Doose H, Gerken H, Leonhardt R, Volzke E, Volz C: Centrencephalic myoclonic-astatic petit mal. Clinical and genetic investigation. Neuropadiatrie 1970, 2:59-78.
• [5]Commission on Classification and Terminology of the International League Against Epilepsy: Proposal for revised classification of epilepsies and epileptic syndromes Epilepsia 1989, 30:389-99.
• [6]Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, van Emde Boas W, et al.: Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005–2009. Epilepsia 2010, 51:676-85.
• [7]Venot M, Weiss N, Espinoza S, Imbert A, Tadie J-M, Fagon J-Y, et al.: Improvement of early diagnosed post-anoxic myoclonus with levetiracetam. Intensive Care Med 2011, 37:177-9.
• [8]Labate A, Colosimo E, Gambardella A, Leggio U, Ambrosio R, Quattrone A: Levetiracetam in patients with generalised epilepsy and myoclonic seizures: an open label study. Seizure J Br Epilepsy Assoc 2006, 15:214-8.
• [9]Striano P, Coppola A, Pezzella M, Ciampa C, Specchio N, Ragona F, et al.: An open-label trial of levetiracetam in severe myoclonic epilepsy of infancy. Neurology 2007, 69:250-4.
• [10]Striano P, Sofia V, Capovilla G, Rubboli G, Di Bonaventura C, Coppola A, et al.: A pilot trial of levetiracetam in eyelid myoclonia with absences (Jeavons syndrome). Epilepsia 2008, 49:425-30.
• [11]Kelley SA, Kossoff EH: Doose syndrome (myoclonic-astatic epilepsy): 40 years of progress. Dev Med Child Neurol 2010, 52:988-93.
• [12]Wheless JW, Sankar R: Treatment strategies for myoclonic seizures and epilepsy syndromes with myoclonic seizures. Epilepsia 2003, 44:27-37.
• [13]Neubauer BA, Hahn A, Doose H, Tuxhorn I: Myoclonic-astatic epilepsy of early childhood–definition, course, nosography, and genetics. Adv Neurol 2005, 95:147-55.
• [14]Kilaru S, Bergqvist AG: Current treatment of myoclonic astatic epilepsy: clinical experience at the Children's Hospital of Philadelphia. Epilepsia 2007, 48:1703-7.
• [15]Kluger G, Haberlandt E, Kurlemann G, Ernst J-P, Runge U, Schneider F, et al.: First European long-term experience with the orphan drug rufinamide in childhood-onset refractory epilepsy. Epilepsy Behav 2010, 17:546-8.
• [16]Oguni H, Tanaka T, Hayashi K, Funatsuka M, Sakauchi M, Shirakawa S, et al.: Treatment and long-term prognosis of myoclonic-astatic epilepsy of early childhood. Neuropediatrics 2002, 33:122-32.
• [17]Fejerman N, Caraballo R, Cersosimo R: Ketogenic diet in patients with Dravet syndrome and myoclonic epilepsies in infancy and early childhood. Adv Neurol 2005, 95:299-305.
• [18]Caraballo RH, Cersósimo RO, Sakr D, Cresta A, Escobal N, Fejerman N: Ketogenic diet in patients with myoclonic-astatic epilepsy. Seizure J Br Epilepsy Assoc 2006, 4:4.
• [19]Kröll-Seger J, Mothersill IW, Novak S, Sälke-Kellermann RA, Krämer G: Levetiracetam-induced myoclonic status epilepticus in myoclonic-astatic epilepsy: a case report. Epileptic Disord 2006, 8:213-8.
• [20]Dulac O, Kaminska A: Use of lamotrigine in Lennox-Gastaut and related epilepsy syndromes. J Child Neurol 1997, 12(Suppl 1):S23-8.
• [21]Wallace SJ: Myoclonus and epilepsy in childhood: a review of treatment with valproate, ethosuximide, lamotrigine and zonisamide. Epilepsy Res 1998, 29:147-54.